Sleep Profile of Patients With Septo-optic Dysplasia

Blindness Clinical Trial

Official title:

Characterization of Sleep Features in Pediatric Patients With Septa-optic Dysplasia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06262152
• Other study ID #: 49187/2023
• Status: Recruiting
• Start date: December 20, 2023
• Est. completion date: May 20, 2025

Study information

• Verified date: February 2024
• Source: IRCCS National Neurological Institute "C. Mondino" Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to evaluate sleep of patients with septo-optic dysplasia compared to patients with an isolated disorder of peripheral visual system and patients with corpus callosum agenesis since both visus defict and agenesis of corpus callosum might be present SOD but associated to other features / structural and functional anomalies.

Included patients and their caregivers will be asked to compile standardize sleep questionnaires and a sleep screening through an interview will be scheduled. Patients will be asked to wear an actigraph on their non-dominant hand wrist for 7 days.

Description:

The primary objective of this study is to evaluate sleep of patients with septo-optic dysplasia compared to patients with an isolated disorder of peripheral visual system and patients with corpus callosum agenesis since both visus defict and agenesis of corpus callosum might be present SOD but associated to other features / structural and functional anomalies.

The secondary aims of this study are the following:

1. identify which factors such as clinical and neuroanatomical features including sensory experience influence sleep outcome and how

2. describe melatonin profile of patients with SOD

3. describe sleep EEG of patients with SOD

Three groups of patients will be included:

• Group A: patients with septo-optic dysplasia

• Group B: patients with disorder of peripheral visual system

• Group C: patients with Corpus Callosum agenesis

This is an observational monocentric study. The procedures in the study that are not included in current clinical practice in the follow-up pathway of the included patients are the following:

• administration of standardized sleep questionnaires (Pittsburgh Sleep Quality Index:

self-completed questionnaire assessing sleep quality over a 1-month time interval;Epworth Sleepiness Scale: self-completed questionnaire assessing daytime sleepiness; Children sleep habits questionnaire)

• 7 days actigraph recording through wearing of Actiwatch spectrum plus at home

• Performance of Sleep EEG

• Performance of blood and salivary sampling for melatonin dosing (for each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: May 20, 2025
• Est. primary completion date: January 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 18 Years

Eligibility

Inclusion criteria group A:

• diagnosis of SOD or SOD plus syndrome with or without a defined genetic diagnosis

• age 3-18 years

• availability of at least 2 serial sleep EEGs performed during clinical follow-up

• stable drug therapy in the last three months

Inclusion criteria group B:

• diagnosis of congenital or early acquired isolated peripheral visual deficit with or without a known genetic diagnosis (e.g., congenital cataract, inherited retinal dystrophies, isolated eye maldevelopment).

• age 3-18 years

• grating or visual acuity < 3/10

• availability of serial sleep EEGs performed during clinical follow-up

• stable drug therapy in the last three months

Inclusion criteria group C

• isolated corpus callosum agenesis at brain MRI

• age 3-18 years

• availability of at least 2 serial sleep EEGs performed during clinical follow-up

• stable drug therapy in the last three months

Exclusion criteria group A:

• absence of informed consent

• severe Intellectual disability and/or severe motor impairment

• melatonin assumption

Exclusion criteria group B:

• absence of informed consent

• CNS involvement ( malformations/ lesions)

• severe Intellectual disability and/or severe motor impairment

• melatonin assumption

Exclusion criteria group C

• absence of informed consent

• severe Intellectual disability and/or severe motor impairment

• melatonin assumption

Related Conditions & MeSH terms

• Blindness
• Septo-Optic Dysplasia

Intervention

Diagnostic Test:
• Actigraphy, blood and salivary sample, and sleep evaluation
For each subject, one 4 mL blood and one 2 mL saliva samples will be collected at each assessment. 7 days actigraph recording through wearing of Actiwatch spectrum plus at home Standardized sleep questionnaire administration

Locations

Country	Name	City	State
Italy	IRCCS Casimiro Mondino Foundation	Pavia	PV

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS National Neurological Institute "C. Mondino" Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sleep profile ( Sleep quality, sleep efficiency) of patients with SOD	SLEEP QUALITY will be assessed through standardized questionnaires :Pittsburgh Sleep Quality Index: self-completed questionnaire ;Epworth Sleepiness Scale: self-completed questionnaire assessing daytime sleepiness; Children sleep habits questionnaire .; Sleep quality and sleep-wake cycle will be evaluated, namely Child's inability to go to bed, the delay in falling asleep, sleep duration, overnight awakenings, anxiety related to sleep, parasomnia, respiratory disorders, and daytime sleepiness.; SLEEP EFFICIENCY will be measured by actigraphic assessment of sleep efficiency (the ratio of total sleep time to sleep period), total nighttime sleep duration, rest activity and number of awakenings.	12 months
Secondary	melatonin profile of patients with SOD	For each subject, blood and and saliva samples will be collected and Serum and salivary concentrations of melatonin and of its main metabolite 6-hydroxymelatonin will be measured in samples collected from all patients by using a validated LC-MS method with minor modifications (Magliocco et al 2021).	12 months
Secondary	Sleep EEG description of patients with SOD	A Sleep EEG recording will also be scheduled at the time of study inclusion/evaluation. Previously performed EEG will be revised. EEG assessment will include the analysis of background activity, presence/absence of physiological sleep elements, interictal discharges, sleep macrostructure and microstructure ( spindle characteristics).	12 months